Journal
CELL DEATH DISCOVERY
Volume 4, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41420-018-0059-0
Keywords
-
Categories
Funding
- Ministry of Health, Labour and Welfare (MHLW) for the third-term Comprehensive 10-year Strategy for Cancer Control, Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and development, AMED [15ck0106008h0002, 16ck0106008h0003]
- National Cancer Center Research and Development Fund [23-B-27[23-A-37], 29-E-6, 23-A-7]
Ask authors/readers for more resources
Anaplastic lymphoma kinase (ALK) is an oncogenic receptor tyrosine kinase that is activated by gene amplification and mutation in neuroblastomas. ALK inhibitors can delay the progression of ALK-driven cancers, but are of limited use owing to ALK inhibitor resistance. Here, we show that resistance to ALK inhibitor in ALK-driven neuroblastomas can be attenuated by combination treatment with a p53 activator. Either ALK inhibition or p53 activator treatment induced cell cycle arrest, whereas combination treatment induced apoptosis, and prevented tumour relapse both in vitro and in vivo. This shift toward apoptosis, and away from cell-cycle arrest, in the presence of an ALK inhibitor and a p53 activator, is mediated by inhibition of the ALK-AKT-FOXO3a axis leading to a specific upregulation of SOX4. SOX4 cooperates with p53 to upregulate the pro-apoptotic protein PUMA. These data therefore suggest a novel combination therapy strategy for treating ALK-driven neuroblastomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available